Ipsen

IPN

FR0010259150

Pharmaceuticals

Real-time Euronext Paris Other stock markets 13:10:27 05/07/2024 BST			5-day change	1st Jan Change
112.3 ^EUR	-1.75%		-1.92%	+4.08%

07-02	Ipsen Expands Partnership with Exelixis for Cabometyx	MT
07-02	Ipsen extends collaboration with Exelixis	CF

IPSEN : Buy back programme Art 5 of MAR Week 26 2024

July 02, 2024 at 05:03 pm

IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2024

02 Jul 2024 18:00 CEST

Issuer

IPSEN

Aggregatedpresentationbydayandbymarket

Purchases of own shares from June 24th to 28th 2024

Name of the Issuer	Identity code of the Issuer	Day of the transaction	Identity code of the financial instrument	Total daily volume (in number of shares)	Daily weighted average purchase price of the shares	Market (MIC Code)
IPSEN	549300M6SGDPB4Z94P11	24/06/2024	FR0010259150	3 455	115,8742	XPAR
IPSEN	549300M6SGDPB4Z94P11	24/06/2024	FR0010259150	545	116,2877	CEUX
IPSEN	549300M6SGDPB4Z94P11	25/06/2024	FR0010259150	4 500	116,4528	XPAR
IPSEN	549300M6SGDPB4Z94P11	25/06/2024	FR0010259150	500	116,3130	CEUX
IPSEN	549300M6SGDPB4Z94P11	26/06/2024	FR0010259150	10 000	114,9442	XPAR
IPSEN	549300M6SGDPB4Z94P11	27/06/2024	FR0010259150	8 000	114,8483	XPAR
IPSEN	549300M6SGDPB4Z94P11	28/06/2024	FR0010259150	5 998	114,6438	XPAR
IPSEN	549300M6SGDPB4Z94P11	28/06/2024	FR0010259150	3 155	114,6421	CEUX
IPSEN	549300M6SGDPB4Z94P11	28/06/2024	FR0010259150	425	114,6134	TQEX
IPSEN	549300M6SGDPB4Z94P11	28/06/2024	FR0010259150	216	114,6148	AQEU
			TOTAL	36 794	115,1530

Attachment

EN_IPSEN - Buy-back programme - Art 5 of MAR - Week 26_2024

Source

Ipsen Pharma

Provider

GlobeNewswire

Company Name

IPSEN

ISIN

FR0010259150

Symbol

IPN

Market

Euronext

Attachments

Original Link
Permalink

Disclaimer

Ipsen SA published this content on 02 July 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 July 2024 16:02:01 UTC.

Latest news about Ipsen

Ipsen Expands Partnership with Exelixis for Cabometyx	07-02	MT
Ipsen extends collaboration with Exelixis	07-02	CF
IPSEN : UBS remains positive ahead of quarterly results	06-26	CF
Ipsen: share price soars, UBS confirms its recommendation	06-12	CF
IPSEN : UBS remains Buy after FDA approval	06-12	CF
Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis	06-11	CI
Ipsen: FDA grants approval for treatment	06-11	CF
Ipsen Secures US FDA's Accelerated Approval for Liver Disease Drug Iqirvo	06-11	MT
Genfit Partner Ipsen Gets FDA Accelerated Approval for Primary Biliary Cholangitis Treatment	06-10	MT
Ipsen's Rare Liver Disease Treatment Gets FDA OK	06-10	DJ
US FDA grants accelerated approval to Genfit and Ipsen's liver disease drug	06-10	RE
US FDA approves Genfit and Ipsen's liver disease drug	06-10	RE
Ipsen Expands Oncology Research Collaboration with Marengo Therapeutics	06-07	MT
Ipsen: research partnership with Marengo extended	06-07	CF
Ipsen Hires New Chief Corporate Affairs Officer	06-06	MT
Ipsen: new Chief Corporate Affairs Officer	06-06	CF
Ipsen: new positive data in PBC	06-05	CF
Ipsen: mandate to an ISP for share buybacks	06-03	CF
Ipsen: new employee shareholding operation	05-31	CF
Ipsen S.A. Approves Dividend, Payable on 3 June 2024	05-28	CI
Ipsen: share price up, analyst raises target	05-14	CF
IPSEN : Barclays raises its target price	05-14	CF
Ipsen Announces Executive Changes	05-02	CI
Ipsen: new President for North America	05-02	CF
IPSEN : Better-than-expected Q1; guidance unchanged	04-24

Chart Ipsen

Duration

Period

More charts

Company Profile

Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (75.2%); - neuroscience (21.1%); - rare diseases (3.7%). At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide. Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).

Sector

Pharmaceuticals

Calendar

23/07/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , CAC Mid 60

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

IPSEN : Better-than-expected Q1; guidance unchanged

April 24, 2024 at 03:50 pm

More Strategies

Ratings for Ipsen

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

114.3 EUR

Average target price

127.3 EUR

Spread / Average Target

+11.35%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
IPSEN	+4.08%	10.21B
ELI LILLY AND COMPANY	+54.07%	809B
NOVO NORDISK A/S	+39.78%	624B
JOHNSON & JOHNSON	-7.05%	351B
MERCK & CO., INC.	+15.44%	319B
ABBVIE INC.	+5.72%	289B
ASTRAZENECA PLC	+14.26%	240B
ROCHE HOLDING AG	+0.78%	219B
NOVARTIS AG	+14.73%	220B
AMGEN INC.	+7.42%	166B

Other Pharmaceuticals

Ipsen

Equities

IPN

FR0010259150

Pharmaceuticals

IPSEN : Buy back programme Art 5 of MAR Week 26 2024

EPS Revisions